This review focuses on areas of somewhat recent discovery that relate in large part to the
areas studied or under investigation by the authors over the last 10 years. Readers are …

Objective To review the pharmacology, research developments, and clinical uses of
pimobendan Data Sources Original research articles and clinical studies from 1984 to …

Background The benefit of pimobendan in delaying the progression of preclinical dilated
cardiomyopathy (DCM) in Dobermans is not reported. Hypothesis That chronic oral …

Cardiac troponin‐I (cTnI) is a highly sensitive and specific marker of myocardial injury and
can be detected in plasma by immunoassay techniques. The purpose of this study was to …

Objective—To determine the correlation between activity as measured by an accelerometer
and videographic measurements of movement and mobility in healthy dogs. Animals—4 …

Twenty‐one days after they had calved, the vaginas of 34 cows were examined with a clean
gloved hand, and 26 cows were left unexamined. Swabs were collected from the lumen of …

Seventy-six dogs with clinical acquired atrioventricular valvular disease were evaluated to
determine the efficacy of pimobendan (n= 41) versus benazepril hydrochloride (n= 35) in a …

Objective: To review the association between clinical signs and diagnostic findings and the
survival time of dogs with dilated cardiomyopathy (DCM), and any influence of treatment …

Background: Despite traditional therapy of a diuretic, angiotensin converting enzyme
inhibitor, digoxin, or a combination of these drugs, survival of dogs with dilated …

Objective—To assess survival time and adverse events related to the administration of
pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic …